# An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

> **NCT02632409** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 709 (actual)

## Conditions studied

- Various Advanced Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02632409
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03-22
- **Primary completion:** 2020-07-17
- **Final completion:** 2027-05-27
- **Target enrollment:** 709 (ACTUAL)
- **Last updated:** 2025-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632409, "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02632409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*